secwatch.observer — SEC 8-K summary
======================================

Issuer:     ELUTIA INC. (ELUT)
CIK:        0001708527
Form:       8-K
Filed at:   2025-11-06T23:59:59+00:00
Accession:  0001104659-25-107741
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Elutia Q3 revenue $3.3M, closes $88M BioEnvelope sale to Boston Scientific, pays off debt
--------------------------------------------------------------------------------

- Net sales $3.3M (down from $3.7M YoY); loss from operations $5.2M vs $9.2M loss a year ago.
- Closed sale of BioEnvelope business to Boston Scientific for $88M; used $27.8M to repay SWK loan facility in full.
- Advancing NXT-41x for plastic/reconstructive surgery; FDA clearance of base matrix expected 2H26, drug-eluting version 1H27.
- Cash balance $4.7M at Sep 30, 2025; received $80.3M net proceeds on Oct 1, 2025 after closing and escrow.
- Settled 7 additional FiberCel cases, leaving only 6 unresolved; Guido J. Neels appointed to Board.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1708527/000110465925107741/0001104659-25-107741-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1708527/000110465925107741/tm2530506d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-107741

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer